Description
Indication & Scope
Tislelizumab Injection (BaiZeAn®)is a humanized IgG4 anti-PD-1 monoclonal antibody. It binds to PD-1 on T cells, blocks PD-1/PD-L1 immune checkpoint pathway, restores T cell anti-tumor immune function, activates systemic anti-tumor immunity to kill cancer cells.
- Mechanism
Block PD-1 checkpoint pathway, restore T cell anti-tumor immune activity - Drug class
PD-1 Immune Checkpoint Inhibitor / Monoclonal Antibody Anti-tumor Immunotherapy - Clinical use
Multiple malignant tumors including classical Hodgkin’s lymphoma, urothelial carcinoma, non-small cell lung cancer, hepatocellular carcinoma, esophageal squamous cell carcinoma, nasopharyngeal carcinoma and gastric cancer
| Generic Name | Tislelizumab Injection |
| Brand Name | BaiZeAn® |
| Ingredient | Tislelizumab |
| Dosage Form | Injection |
| Package | 10ml:100mg/vial |
| Conditions Treated | Relapsed/refractory classical Hodgkin’s lymphoma;Locally advanced/metastatic urothelial carcinoma with high PD-L1 expression;Advanced non-small cell lung cancer;Advanced hepatocellular carcinoma;MSI-H/dMMR locally advanced or metastatic solid tumors;Advanced esophageal squamous cell carcinoma;Nasopharyngeal carcinoma, gastric cancer and other advanced malignancies |
| Taboos | Hypersensitivity to tislelizumab or any excipients |
| Place of origin | Guangdong,China |
| Priscription Type | Prescription Drug, Class B Medicare |
| Storage Conditions | Store at 2℃-8℃, protected from light, do not freeze |
| Manufacturer | BeOneMedicines Ltd. |
| Registration Authority | National Medical Products Administration (NMPA) |
| Approval number | S20190045 |
| Date of Revision | December 18, 2025 |
| Shelf Life | 24 months |
How to use ?
Recommended Dose: 200mg, intravenous infusion, once every 3 weeks; first infusion ≥60 minutes, subsequent infusions ≥30 minutes, do not rapid bolus
Time: Intravenous slow infusion, do not give as rapid IV push
Interaction: Risk of severe immune-related adverse events when combined with immunosuppressants/corticosteroids; monitor closely; do not mix directly with other infusions
Side effects: Immune-related adverse reactions (thyroid dysfunction, pneumonitis, hepatitis, colitis), fatigue, anemia, rash, elevated liver enzymes, infusion reactions
Important Notice
This product shall only be used for post-exposure rabies prophylaxis by professional medical staff. It must be applied combined with rabies vaccine and injected via wound infiltration plus intramuscular routes as specified. Do not administer intravenously or alter the dosage at will. Hypersensitivity monitoring is required throughout the whole injection process.
Packaging & Shipping
Packaging
Original manufacturer’s packaging with secure export carton. Customized export packaging is available upon request.
Shipping Methods
Express Courier (EMS, DHL, FedEx, UPS), Air Freight, and Sea Freight. Cold-chain transportation is available for products requiring temperature-controlled logistics.
Export Support
Certificate of Analysis
GMP Certificate
Commercial Invoice
Packing List & CPP
Cold Chain Logistics
Customs Documentation
Scientific and regulatory sources
FAQ
What unique structural advantage does tislelizumab have?
It has Fc segment modification to reduce macrophage phagocytosis and improve efficacy.
How to manage grade 3 immune-related adverse reactions?
Suspend medication and initiate glucocorticoid therapy.
What is the antibody subtype of tislelizumab?
Humanized IgG4 anti-PD-1 monoclonal antibody.
How long is the first infusion time?
No less than 60 minutes.
BaiZeAn® | Tislelizumab Injection | Urothelial Carcinoma | DengYueRX
INN: Tislelizumab
Indications: Urothelial Carcinoma
Dosage Form: Injection
Strength: 10ml:100mg/Vial
Original price was: $327.73.$278.57Current price is: $278.57.
